Emergent Biosolutions EBS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $209.1M+98.0% | $105.6M-5.5% | $111.7M-82.6% | $642.6M+11.5% | ||
| $84.2M-45.5% | $154.5M-19.1% | $191M+20.0% | $159.2M-42.9% | ||
| $343.4M+10.2% | $311.7M-5.2% | $328.9M-6.2% | $350.7M+1.8% | ||
| $662.5M+10.7% | $598.7M-11.9% | $679.5M-43.9% | $1.21B-4.7% | ||
| $205.4M-24.1% | $270.6M-29.3% | $382.8M-53.2% | $817.6M+2.2% | ||
| $436.5M-13.0% | $501.5M-11.5% | $566.6M-22.3% | $728.8M+20.5% | ||
| $1.32B-5.1% | $1.39B-23.8% | $1.82B-42.4% | $3.17B+7.1% | ||
| $55.6M-8.7% | $60.9M-45.7% | $112.2M+8.4% | $103.5M-19.7% | ||
| $5M+4.2% | $4.8M-82.4% | $27.2M+3.0% | $26.4M+126% | ||
| $132.2M-18.6% | $162.4M-75.1% | $651.3M-47.0% | $1.23B+229% | ||
| $572.1M-13.8% | $663.7M+48.6% | $446.5M-0.4% | $448.5M-44.6% | ||
| $21.7M+34.0% | $16.2M+189% | $5.6M-30.0% | $8M-81.5% | ||
| 200M+199,900% | 100K0.0% | 100K0.0% | 100K0.0% | ||
| -$159.8M+24.8% | -$212.4M-874% | -$21.8M-103% | $738.7M-22.3% | ||
| $522.6M+8.2% | $482.8M-25.6% | $649.3M-53.2% | $1.39B-13.9% | ||
| $1.32B-5.1% | $1.39B-23.8% | $1.82B-42.4% | $3.17B+7.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Emergent Biosolutions's total assets?
- Emergent Biosolutions (EBS) holds $1.3B in total assets, down 7.4% year over year.
- How much debt does Emergent Biosolutions have?
- Emergent Biosolutions carries $584.6M in total debt against $523.1M of shareholders' equity, a debt-to-equity ratio of 1.12.
- How much cash does Emergent Biosolutions have?
- Emergent Biosolutions holds $161.5M in cash and equivalents.
- Can Emergent Biosolutions cover its short-term obligations?
- Its current ratio is 4.29 — current assets exceed current liabilities.
- Where does Emergent Biosolutions's balance sheet data come from?
- Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
